Literature DB >> 16782967

Isolation and characterization of low sulfated heparan sulfate sequences with affinity for lipoprotein lipase.

Dorothe Spillmann1, Aivar Lookene, Gunilla Olivecrona.   

Abstract

Lipoprotein lipase (LPL), which is an important enzyme in lipid metabolism, binds to heparan sulfate (HS) proteoglycans. This interaction is crucial for several aspects of LPL function, such as intracellular/extracellular transport and high capacity attachment to cell surfaces. Retention of LPL on the capillary walls, and elsewhere, via HS chains is most likely affected by the quality and quantity of HS present. Earlier studies have demonstrated that LPL interacts with highly sulfated HS and heparin oligosaccharides. Since such structures are relatively rare in endothelial HS, we have re-addressed the question of physiological ligand structures for LPL by affinity purification of end-labeled oligosaccharides originating from heparin and HS on immobilized LPL. By a combination of chemical modification and fragmentation of the bound material we identified that the bound fraction contained modestly sulfated oligosaccharides with an average sulfation of one O-sulfate per disaccharide unit and tolerates N-acetylated glucosamine residues. Therefore LPL, containing several clusters of positive charges on each subunit, may constitute an ideal structure for a protein that needs to bind with reasonable affinity to a variety of modestly sulfated sequences of the type that is abundant in HS chains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782967     DOI: 10.1074/jbc.M604702200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.

Authors:  Jennifer M MacArthur; Joseph R Bishop; Kristin I Stanford; Lianchun Wang; André Bensadoun; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance.

Authors:  Kristin I Stanford; Lianchun Wang; Jan Castagnola; Danyin Song; Joseph R Bishop; Jillian R Brown; Roger Lawrence; Xaiomei Bai; Hiroko Habuchi; Masakazu Tanaka; Wellington V Cardoso; Koji Kimata; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 3.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

4.  On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.

Authors:  Oleg Kovrov; Kristian Kølby Kristensen; Erika Larsson; Michael Ploug; Gunilla Olivecrona
Journal:  J Lipid Res       Date:  2019-01-27       Impact factor: 5.922

5.  Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.

Authors:  Kristin I Stanford; Joseph R Bishop; Erin M Foley; Jon C Gonzales; Ingrid R Niesman; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

6.  A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase.

Authors:  Kristian K Kristensen; Søren Roi Midtgaard; Simon Mysling; Oleg Kovrov; Lars Bo Hansen; Nicholas Skar-Gislinge; Anne P Beigneux; Birthe B Kragelund; Gunilla Olivecrona; Stephen G Young; Thomas J D Jørgensen; Loren G Fong; Michael Ploug
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-13       Impact factor: 11.205

7.  Rosette-Disrupting Effect of an Anti-Plasmodial Compound for the Potential Treatment of Plasmodium falciparum Malaria Complications.

Authors:  Jun-Hong Ch'ng; Kirsten Moll; Maria Del Pilar Quintana; Sherwin Chun Leung Chan; Ellen Masters; Ernest Moles; Jianping Liu; Anders B Eriksson; Mats Wahlgren
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.